BPC-157 research: what the published studies show

Tendon and Fibroblast Studies

Several rat studies have examined BPC-157 in connective-tissue injury models.

In the first of those, the Achilles tendon was sharply transected from the calcaneal bone. Over 21 days researchers reported improvements across four measures: functional, biomechanical, macroscopic and immunohistochemical.^[1] The same study also co-administered 6α-methylprednisolone, which impaired healing, and BPC-157 was reported to substantially reduce that impairment.^[1] This is an effect on damage the experimenters caused, not an independent improvement.

A second study used a rat medial collateral ligament transection model, comparing once-daily intraperitoneal, per-oral and topical administration. It reported consistent improvement over 90 days by the same four measure types, with histology in place of immunohistochemistry.^[2]Cell-level findings are more qualified.

In tendon fibroblasts cultured from rat Achilles tendon, proliferation was not directly affected by BPC-157, as measured by MTT assay.^[3] What researchers saw instead was accelerated outgrowth from tendon explants ex vivo, better cell survival under oxidative stress, and dose-dependent migration in vitro.^[3] The authors suggest these are mediated by activation of the FAK-paxillin pathway.^[3]

A later study in the same cell type found dose- and time-dependent up-regulation of the growth hormone receptor, at both mRNA and protein level.^[4] Proliferation rose only when growth hormone was added afterwards to treated cells, an effect the authors framed as potentiating growth hormone rather than driving growth on its own.^[4]

Gastric and Mucosal Studies

The earliest work in this reference set dates from 1994, predating the tendon research by more than a decade, and it concerns the gastric and duodenal mucosa rather than connective tissue.^[5]

Researchers tested BPC-157 in rats across three models of mucosal injury: 48-hour restraint stress, subcutaneous cysteamine, and intragastric 96% ethanol.^[5] It was given either intraperitoneally or intragastrically, and before, alongside or after the injury.^[5]

What makes the study notable is its comparative design: of every agent tested, only the BPC-157 regimens were reported effective across all three models.^[5]

Bromocriptine, amantadine, famotidine, cimetidine and somatostatin were reported ineffective in the restraint-stress model.^[5] Glucagon, NPY and secretin produced a dose-dependent protective effect against cysteamine, and a partial effect under ethanol that varied with conditions.^[5] CCK(26-30) was reported not effective.^[5]

On mechanism the authors are careful. Drawing on Monastral blue studies, they write that the benefit appears to be related to a strong endothelial protection.^[5] That is their hedge, carried across as written, not a demonstrated mechanism.

Angiogenesis and Vascular Signaling

Two groups have studied BPC-157 in relation to blood-vessel formation, and their cell-culture results do not agree.

In the first, vessel density rose in a chick chorioallantoic membrane assay and endothelial tube formation rose in vitro.^[6] In rats with an ischemic hind limb, blood flow recovered faster, measured by laser Doppler scanning.^[6] Histology of that muscle showed more vessels and stronger vascular expression of VEGFR2.^[6] In cultured human vascular endothelial cells, VEGFR2 mRNA and protein rose, but VEGF-A did not.^[6]

The authors link this to VEGFR2 internalisation and the VEGFR2-Akt-eNOS pathway, noting that both tube formation and pathway activation were suppressed by dynasore, an endocytosis inhibitor.^[6]

An earlier study, working with cell culture alongside crushed and transected rat muscle and tendon, reported no direct angiogenic effect on cell cultures.^[7] In the treated animals, immunohistochemistry showed modulated angiogenesis with up-regulated VEGF expression.^[7]

So the animal results agree more closely than the cell-culture ones, and the disagreement between the two cell-culture findings is not resolved within the cited work.

State of the Evidence

A 2025 systematic review of BPC-157 in orthopaedic sports medicine identified 544 articles published between 1993 and 2024, and included 36 after screening: thirty-five preclinical, one clinical.^[8]

The review suggests BPC-157 enhances growth hormone receptor expression, along with several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines.^[8] In preclinical models it reports improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bony injuries.^[8] It describes the compound as metabolised in the liver and cleared by the kidneys, with a half-life of under 30 minutes.^[8]

The review is explicit about the limits of that evidence, and those qualifications belong with its conclusion. It grades its evidence base as level IV and level V studies, and states that BPC-157 shows promise for promoting recovery from musculoskeletal injuries, not that it does so.^[8]

On safety it records no adverse effects across several organ systems in preclinical studies, and no clinical safety data found at all.^[8] Adverse effects remain possible, it notes, through unregulated manufacturing, contamination, or simply unknown clinical safety.^[8] It adds that the compound lacks US Food and Drug Administration approval, and that its use is banned in professional sports.^[8]

One further limitation is not about the studies but about who ran them. A substantial share of the published BPC-157 literature comes from a single research group, which leaves independent replication an open question.